In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 |
| 10-K | 10-K | 10-K | S-1/A |
Revenues: |
Zilxi | 2.3 | | | |
Amzeeq | 7.2 | | | |
Qbrexza | 26.7 | 17.1 | | |
Other | 37.4 | 46.1 | | |
Total revenues [+] | 73.7 | 63.1 | 44.5 | 34.9 |
Products | 71.0 | 63.1 | 44.5 | 34.9 |
Other income | 2.7 | | | |
Revenue growth [+] | 16.7% | 41.8% | 27.5% | |
Qbrexza | 56.6% | | | |
Accutane | 82.8% | | | |
Cost of goods sold | 30.8 | 32.1 | 14.6 | 0.0 |
Gross profit | 42.9 | 31.1 | 29.9 | 34.9 |
Gross margin | 58.2% | 49.2% | 67.2% | 100.0% |
Selling, general and administrative | 59.5 | 39.8 | 22.1 | 19.1 |
Research and development | 10.9 | 2.7 | | |
Other operating expenses | | 23.4 | | 10.5 |
EBITDA [+] | | | 9.3 | |
EBITDA growth | -28.3% | -449.4% | 76.4% | |
EBITDA margin | -31.5% | -51.3% | 20.8% | 15.1% |
Depreciation | | | 0.0 | |
EBITA | -23.2 | -32.4 | 9.3 | 5.3 |
EBITA margin | -31.5% | -51.3% | 20.8% | 15.1% |
Amortization of intangibles | 4.3 | 2.5 | 1.4 | |
EBIT [+] | -27.5 | -34.9 | 7.9 | 5.3 |
EBIT growth | -21.1% | -544.3% | 49.3% | |
EBIT margin | -37.4% | -55.2% | 17.6% | 15.1% |
Interest expense, net [+] | 2.0 | 7.0 | 0.7 | |
Interest expense | 2.0 | 7.0 | 0.7 | |
Interest income | 0.1 | 0.0 | | |
Other income (expense), net [+] | -0.1 | -0.4 | | -0.3 |
Gain (loss) on derivative instruments | | 0.4 | | |
Gain (loss) on foreign currency transactions | 0.1 | | | |
Pre-tax income | -29.6 | -42.4 | 7.2 | 5.0 |
Income taxes | 0.1 | 1.6 | 1.9 | 1.4 |
Tax rate | | | 26.1% | 27.6% |
Net income | -29.6 | -44.0 | 5.3 | 0.0 |
Net margin | -40.2% | -69.7% | 11.9% | 0.0% |
|
Basic EPS [+] | ($1.69) | ($4.32) | $0.58 | |
Growth | -60.9% | -846.6% | | |
Diluted EPS [+] | ($1.69) | ($4.32) | $0.49 | |
Growth | -60.9% | -985.6% | | |
|
Shares outstanding (basic) [+] | 17.5 | 10.2 | 9.1 | |
Growth | 72.0% | 11.5% | | |
Shares outstanding (diluted) [+] | 17.5 | 10.2 | 10.8 | |
Growth | 72.0% | -6.0% | | |
|
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |